In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
History Channel “Ax Man” Buckin’ Billy Ray Smith endorses soy-based chainsaw oil
In Maryland, U.S. Soy and Stanley Black & Decker outdoor brand DEWALT have developed soy-based Bar & Chain Biodegradable Oil for chainsaws and other...
Meatable achieves “cell to sausage” in just 4 days
In the Netherlands, Meatable has reached an important milestone in its efforts to produce cultivated meat at scale—the transformation of pluripotent stem cells into...
Reformation launches castor oil swimwear line
In Los Angeles, popular clothing brand Reformation has released a new swimwear line that emphasizes the use “planet-friendly,” biobased materials.
The company tapped Italy-based...